Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
Diabetes' Changing Role in Cardiovascular Disease Management, with Diana Isaacs, PharmD
November 7th 2022Following a session examining the application of the latest iterations of cardiometabolic health guidelines, Diana Isaacs, PharmD, discusses how the evolving role of diabetes, and recognition of this role, in cardiovascular disease is reflected at the American Heart Association 2022 Scientific Sessions.
Read More
Hydrochlorothiazide as Effective as Chlorthalidone for Preventing CVD, Death in Hypertension
November 5th 2022Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.
Read More
Torsemide Provides No Benefit Over Furosemide for Mortality, Hospitalization in Heart Failure
November 5th 2022Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.
Read More
Many Older Adults Not Receiving Adequate Hypertensive Therapy, with Deepak Bhatt, MD, MPH
November 5th 2022An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.
Read More
Published on October 13, the latest scientific statement from the American Heart Association highlights the current role of patient-reported outcome measures in the management of peripheral artery disease as well as future considerations for optimizing this role and benefits in care.
Read More
Dapagliflozin's Benefit in HFpEF Reaches Significance Within 2 Weeks, Study Finds
October 3rd 2022A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.
Read More
Rethinking Statins: Time for Primordial Prevention?
September 27th 2022Statins and their specific role have been the subject of debate for years. In this feature, 6 leading experts in cardiometabolic health share their perspectives on whether statins should be used in the sense of primordial prevention for ASCVD.
Read More
Dapagliflozin Proves HFpEF Benefit in DELIVER Trial
August 27th 2022Presented at ESC Congress 22, results of the DELIVER trial indicate use of dapagliflozin (Farxiga) was associated with an 18% reduction in the primary outcome, with a 21% reduction in risk observed for worsening heart failure and a 12% reduction in risk observed for cardiovascular death compared with placebo therapy.
Read More
Omnipod 5 Receives Clearance for Use in Ages 2 and Older with Type 1 Diabetes
August 22nd 2022Announced on Aug. 22, the US FDA's clearance of the Omnipod 5 AID system in type 1 diabetes for patients aged 2 years and older comes less than 7 months after receiving clearance in patients aged 6 years and older.
Read More
Dapagliflozin's Heart Failure Benefits Consistent, Regardless of Iron Status at Baseline
August 18th 2022An analysis of DAPA-HF provides insight into the effects of dapagliflozin use on the trial's primary outcome based on iron status at baseline and also sheds light on the impact of dapagliflozin use on iron status at 12 months.
Read More
SURMOUNT-1: Tirzepatide Provides Significant, Sustained Weight Loss in Obesity
June 4th 2022A month and a half after topline results were announced in April, full data from SURMOUNT-1 was presented at ADA 2022 and demonstrate tirzepatide in 5 mg, 10 mg, or 15 mg doses provides superior weight loss compared to placebo therapy, with this weight loss maintained throughout the duration of the trial.
Read More
Tirzepatide (Mounjaro) Wins FDA Approval for Type 2 Diabetes
May 13th 2022Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.
Read More
Dapagliflozin Meets Primary Endpoint in Phase 3 DELIVER Trial
May 5th 2022AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.
Read More
Reducing Sedentary Time By An Hour Per Day Can Provide Health Benefits in Metabolic Syndrome
May 5th 2022A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.
Read More
iLet Bionic Pancreas Shows Promise in Pivotal Trial
May 4th 2022Data from a pivotal trial presented at ATTD 2022 demonstrate the use of the iLet Bionic Pancreas was associated with significant improvements in HbA1c and TIR among a diverse study population of adults and children with type 1 diabetes compared with standard care.
Read More
SURMOUNT-1 Results Tout Tirzepatide's Weight Loss Benefits
April 28th 2022Tirzepatide met both coprimary endpoints in SURMOUNT-1, with use contributing to reductions in body weight of up to 22.5% during the 72-week trial and more than 60% of those receiving the 15 mg dose achieving body weight reductions of 20% or more.
Read More
Calcium Supplementation Could Increase Risk of Death in Older Adults with Cardiovascular Disease
April 28th 2022An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.
Read More
History of Infertility Linked to Increased Risk of Heart Failure in Women
April 19th 2022An analysis of data from more than 35,000 women in the Women's Health Initiative indicates a history of infertility was independently associated with a 16% increase in risk of incident heart failure, with a 27% increase in risk of HFpEF, in postmenopausal women.
Read More
Study Quantifies Life-Years Added from Meeting Treatment Goals in Type 2 Diabetes
April 18th 2022A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.
Read More